Get the Stockscreener App
0.7216
6.15%
0.0418
After Hours:
.70
-0.0216
-2.99%
Virpax Pharmaceuticals Inc stock is traded at $0.7216, with a volume of 301.45K.
It is up +6.15% in the last 24 hours and up +2.15% over the past month.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
See More
Previous Close:
$0.6798
Open:
$0.68
24h Volume:
301.45K
Relative Volume:
0.26
Market Cap:
$3.46M
Revenue:
-
Net Income/Loss:
$-15.19M
P/E Ratio:
-0.5508
EPS:
-1.31
Net Cash Flow:
$-9.85M
1W Performance:
+51.60%
1M Performance:
+2.15%
6M Performance:
-80.39%
1Y Performance:
-90.31%
1-Day Range:
$0.68
$0.77
1-Week Range:
$0.421
$0.78
52-Week Range:
$0.3625
$8.00
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
610-727-4597
Address
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Closing Bell Recap: Virpax Pharmaceuticals Inc (VRPX) Ends at 0.48, Reflecting a 1.06 Upturn - The Dwinnex
Virpax Pharmaceuticals Inc: Navigating a Turbulent Year, Up -95.58% from 52-Week Low - The InvestChronicle
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com India
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Pharmaceuticals, Inc. Announces Board and Committee Changes - Marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals appoints new Vice President - Investing.com India
Virpax Pharmaceuticals extends financing negotiation rights - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new Vice President By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals announces auditor change and board resignation - Investing.com
Virpax Pharmaceuticals Overhauls Leadership and Auditor Amid Concerns - TipRanks
Virpax Pharmaceuticals, Inc. Announces Resignation of Eric Floyd as Board and Committee - Marketscreener.com
Checking in on Vir Biotechnology Inc (VIR) after recent insiders movement - Knox Daily
Visionstate (CVE:VIS) Trading 25% Higher - Defense World
Investing in Viridian Therapeutics Inc (VRDN) Is Getting More Attractive - Knox Daily
Virpax Pharmaceuticals sees board member departure By Investing.com - Investing.com Canada
Virpax Pharmaceuticals sees board member departure - Investing.com
Virpax Pharmaceuticals Announces Key Management Changes - TipRanks
Faruqi & Faruqi Reminds Vicor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
It makes sense and dollars to buy Viridian Therapeutics Inc (VRDN) stock - SETE News
Virax Biolabs Group Ltd Inc. (VRAX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
A closer look at VRAX’s price-to-free cash flow ratio - US Post News
VRDN (Viridian Therapeutics Inc) has impressive results - US Post News
Virpax Pharmaceuticals Inc (VRPX) is looking forward to a strong quarter - SETE News
Virpax Pharmaceuticals Inc (VRPX)’s Market Momentum: Closing Strong at 0.82, Up 0.99 - The Dwinnex
Can you still get a good price for Virpax Pharmaceuticals Inc (VRPX) Shares at this point? - US Post News
Virpax Pharmaceuticals receives $2.5M loan financing - Pennsylvania Business Report
Virpax Pharmaceuticals Inc (VRPX)’s stock rises to 1.20 per share - US Post News
Virpax Pharmaceuticals Reports Q2 2024 Financial Results and Strategic Progress - MyChesCo
Virpax Pharmaceuticals Inc: Navigating Market Fluctuations with a 5.77M Market Cap - The InvestChronicle
Daily Progress: Virpax Pharmaceuticals Inc (VRPX) Gain 8.12, Closing at 0.92 - The Dwinnex
VRPX (Virpax Pharmaceuticals) Momentum Rank : 2 (As of Aug. 20, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year FCF Growth Rate : -39.90% (As of Jun. 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -13.40% (As of Jun. 2024) - GuruFocus.com
Virpax Pharmaceuticals to Present at Sidoti August Virtual Investor Conference - MyChesCo
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decline in Short Interest - Defense World
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024 - InvestorPlace
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Business Wire
Marinus Pharmaceuticals to Announce Q2 Financial Results - MyChesCo
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Virpax Pharmaceuticals gains compliance extension from Nasdaq - Investing.com India
Virpax Pharmaceuticals gains compliance extension from Nasdaq By Investing.com - Investing.com Australia
Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges - TipRanks
Holdings of Virpax Pharmaceuticals Inc (VRPX) are aligned with the stars - SETE News
Ratio Revelations: Virpax Pharmaceuticals Inc (VRPX)’s Financial Metrics in the Spotlight - The Dwinnex
What was Virpax Pharmaceuticals Inc (VRPX)’s performance in the last session? - US Post News
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.35%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):